Combined Oxytocin and Cognitive Behavioral Social Skills Training for Social Function in People With Schizophrenia.

Buchanan RW, Kelly DL, Strauss GP, Gold JM, Weiner E, Zaranski J, Chen S, Blatt F, Holden J, Granholm E

Journal of clinical psychopharmacology1 May 2021Cited by 19 (Europe PMC)

PMID33783399PMCIDPMC8887701DOI10.1097/jcp.0000000000001397PepBankPUB-33783399

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia receiving CBSST, intranasal oxytocin given alongside CBSST did not change social functioning compared with placebo.
In plain wordsIn people with schizophrenia, adding oxytocin spray to skills training did not improve social functioning more than placebo.
Peptide
Oxytocin
Outcome
No significant changeSocial functioning
Study
n = 62
Comparator
Intranasal placebo-oxytocin
Outcome group
Social behavior and cognition · Mental health and mood
Studied dose
36 IU twice a day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego.
Summary · context
Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31).
Report a problemFND-3378339901
02HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia receiving CBSST, intranasal oxytocin given alongside CBSST did not change positive symptoms compared with placebo.
In plain wordsIn people with schizophrenia, adding oxytocin spray did not change positive symptoms more than placebo.
Peptide
Oxytocin
Outcome
No significant changePositive symptoms
Study
n = 62
Comparator
Intranasal placebo-oxytocin
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
36 IU twice a day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego.
Summary · context
Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31).
Report a problemFND-3378339902
03HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia receiving CBSST, intranasal oxytocin given alongside CBSST did not change negative symptoms compared with placebo.
In plain wordsIn people with schizophrenia, adding oxytocin spray did not change negative symptoms more than placebo.
Peptide
Oxytocin
Outcome
No significant changeNegative symptoms
Study
n = 62
Comparator
Intranasal placebo-oxytocin
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
36 IU twice a day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego.
Summary · context
Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31).
Report a problemFND-3378339903
04HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia receiving CBSST, intranasal oxytocin given alongside CBSST did not change defeatist beliefs compared with placebo.
In plain wordsIn people with schizophrenia, adding oxytocin spray did not change defeatist beliefs more than placebo.
Peptide
Oxytocin
Outcome
No significant changeDefeatist beliefs
Study
n = 62
Comparator
Intranasal placebo-oxytocin
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
36 IU twice a day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego.
Summary · context
Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31).
Report a problemFND-3378339904
05HumanRandomized controlled trialEfficacy outcome
In people with schizophrenia receiving CBSST, intranasal oxytocin given alongside CBSST did not change asocial beliefs compared with placebo.
In plain wordsIn people with schizophrenia, adding oxytocin spray did not change asocial beliefs more than placebo.
Peptide
Oxytocin
Outcome
No significant changeAsocial beliefs
Study
n = 62
Comparator
Intranasal placebo-oxytocin
Outcome group
Psychiatric symptoms · Mental health and mood
Studied dose
36 IU twice a day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no significant treatment group differences in social functioning, positive symptoms, negative symptoms, defeatist beliefs, or asocial beliefs.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants (N = 62) with schizophrenia or schizoaffective disorder entered a 24-week, double-blind, placebo-controlled, randomized clinical trial with a 3-month follow-up evaluation at 2 sites: Maryland and San Diego.
Summary · context
Participants were randomized to either intranasal oxytocin 36 IU (3 sprays) twice a day (n = 31) or intranasal placebo-oxytocin (3 sprays) twice a day (n = 31).
Report a problemFND-3378339905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT01752712

Oxytocin and CBSST for People With Schizophrenia

University of Maryland, Baltimoren = 83Jan 2014 to Aug 2016

Schizophrenia · Schizoaffective Disorder

Trial page ClinicalTrials.govUpdated 25 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.